NanoCarrier's FVIIa alliance hits bump but cisplatin tie-up forges ahead
This article was originally published in Scrip
Around a year after they extended an initial 2010 option and research collaboration, the French state-owned company LFB Biotechnologies and the Japanese bioventure NanoCarrier have temporarily ended their attempts to develop a novel sustained-release formulation of LFB's human Factor VIIa product for hemophilia.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.